813 related articles for article (PubMed ID: 34788233)
1. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
Bar KJ; Shaw PA; Choi GH; Aqui N; Fesnak A; Yang JB; Soto-Calderon H; Grajales L; Starr J; Andronov M; Mastellone M; Amonu C; Feret G; DeMarshall M; Buchanan M; Caturla M; Gordon J; Wanicur A; Monroy MA; Mampe F; Lindemuth E; Gouma S; Mullin AM; Barilla H; Pronina A; Irwin L; Thomas R; Eichinger RA; Demuth F; Luning Prak ET; Pascual JL; Short WR; Elovitz MA; Baron J; Meyer NJ; Degnan KO; Frank I; Hensley SE; Siegel DL; Tebas P
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34788233
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.
Ortigoza MB; Yoon H; Goldfeld KS; Troxel AB; Daily JP; Wu Y; Li Y; Wu D; Cobb GF; Baptiste G; O'Keeffe M; Corpuz MO; Ostrosky-Zeichner L; Amin A; Zacharioudakis IM; Jayaweera DT; Wu Y; Philley JV; Devine MS; Desruisseaux MS; Santin AD; Anjan S; Mathew R; Patel B; Nigo M; Upadhyay R; Kupferman T; Dentino AN; Nanchal R; Merlo CA; Hager DN; Chandran K; Lai JR; Rivera J; Bikash CR; Lasso G; Hilbert TP; Paroder M; Asencio AA; Liu M; Petkova E; Bragat A; Shaker R; McPherson DD; Sacco RL; Keller MJ; Grudzen CR; Hochman JS; Pirofski LA; ; Parameswaran L; Corcoran AT; Rohatgi A; Wronska MW; Wu X; Srinivasan R; Deng FM; Filardo TD; Pendse J; Blaser SB; Whyte O; Gallagher JM; Thomas OE; Ramos D; Sturm-Reganato CL; Fong CC; Daus IM; Payoen AG; Chiofolo JT; Friedman MT; Wu DW; Jacobson JL; Schneider JG; Sarwar UN; Wang HE; Huebinger RM; Dronavalli G; Bai Y; Grimes CZ; Eldin KW; Umana VE; Martin JG; Heath TR; Bello FO; Ransford DL; Laurent-Rolle M; Shenoi SV; Akide-Ndunge OB; Thapa B; Peterson JL; Knauf K; Patel SU; Cheney LL; Tormey CA; Hendrickson JE
JAMA Intern Med; 2022 Feb; 182(2):115-126. PubMed ID: 34901997
[TBL] [Abstract][Full Text] [Related]
5. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
6. Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.
Troxel AB; Petkova E; Goldfeld K; Liu M; Tarpey T; Wu Y; Wu D; Agarwal A; Avendaño-Solá C; Bainbridge E; Bar KJ; Devos T; Duarte RF; Gharbharan A; Hsue PY; Kumar G; Luetkemeyer AF; Meyfroidt G; Nicola AM; Mukherjee A; Ortigoza MB; Pirofski LA; Rijnders BJA; Rokx C; Sancho-Lopez A; Shaw P; Tebas P; Yoon HA; Grudzen C; Hochman J; Antman EM
JAMA Netw Open; 2022 Jan; 5(1):e2147331. PubMed ID: 35076699
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma.
Park H; Tarpey T; Liu M; Goldfeld K; Wu Y; Wu D; Li Y; Zhang J; Ganguly D; Ray Y; Paul SR; Bhattacharya P; Belov A; Huang Y; Villa C; Forshee R; Verdun NC; Yoon HA; Agarwal A; Simonovich VA; Scibona P; Burgos Pratx L; Belloso W; Avendaño-Solá C; Bar KJ; Duarte RF; Hsue PY; Luetkemeyer AF; Meyfroidt G; Nicola AM; Mukherjee A; Ortigoza MB; Pirofski LA; Rijnders BJA; Troxel A; Antman EM; Petkova E
JAMA Netw Open; 2022 Jan; 5(1):e2147375. PubMed ID: 35076698
[TBL] [Abstract][Full Text] [Related]
10. "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".
Teofili L; Landolfi R; Cingolani A; Antinori A; Vecchiet J; Sanguinetti M; Gasbarrini A; Pasciuto T; Orlando N; Lamonica S
Trials; 2020 Oct; 21(1):875. PubMed ID: 33092632
[TBL] [Abstract][Full Text] [Related]
11. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G
Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499
[TBL] [Abstract][Full Text] [Related]
12. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
Bihariesingh-Sanchit R; Bansie R; Ramdhani N; Mangroo R; Bustamente D; Diaz E; Fung A Foek C; Thakoer I; Vreden S; Choudhry Z; van 't Wout AB; Diavatopoulos DA; Nierich AP
mBio; 2023 Apr; 14(2):e0337922. PubMed ID: 36815780
[TBL] [Abstract][Full Text] [Related]
13. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.
Körper S; Weiss M; Zickler D; Wiesmann T; Zacharowski K; Corman VM; Grüner B; Ernst L; Spieth P; Lepper PM; Bentz M; Zinn S; Paul G; Kalbhenn J; Dollinger MM; Rosenberger P; Kirschning T; Thiele T; Appl T; Mayer B; Schmidt M; Drosten C; Wulf H; Kruse JM; Jungwirth B; Seifried E; Schrezenmeier H;
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464358
[TBL] [Abstract][Full Text] [Related]
14. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
Trials; 2021 May; 22(1):323. PubMed ID: 33947446
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.
Diago-Sempere E; Bueno JL; Sancho-López A; Rubio EM; Torres F; de Molina RM; Fernández-Cruz A; de Diego IS; Velasco-Iglesias A; Payares-Herrera C; Flecha IC; Avendaño-Solà C; Palomino RD; Ramos-Martínez A; Ruiz-Antorán B
Trials; 2021 Jan; 22(1):70. PubMed ID: 33472681
[TBL] [Abstract][Full Text] [Related]
17. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial.
Self WH; Wheeler AP; Stewart TG; Schrager H; Mallada J; Thomas CB; Cataldo VD; O'Neal HR; Shapiro NI; Higgins C; Ginde AA; Chauhan L; Johnson NJ; Henning DJ; Jaiswal SJ; Mammen MJ; Harris ES; Pannu SR; Laguio-Vila M; El Atrouni W; de Wit M; Hoda D; Cohn CS; McWilliams C; Shanholtz C; Jones AE; Raval JS; Mucha S; Ipe TS; Qiao X; Schrantz SJ; Shenoy A; Fremont RD; Brady EJ; Carnahan RH; Chappell JD; Crowe JE; Denison MR; Gilchuk P; Stevens LJ; Sutton RE; Thomsen I; Yoder SM; Bistran-Hall AJ; Casey JD; Lindsell CJ; Wang L; Pulley JM; Rhoads JP; Bernard GR; Rice TW;
Chest; 2022 Nov; 162(5):982-994. PubMed ID: 35780813
[TBL] [Abstract][Full Text] [Related]
19. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.
Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19.
Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A
Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
